The world's leading automated proofreading software

Help Centre   |   Contact Sales

Preparing for a Paperless Future: How the Medical Device Sector is Embracing e-labelling

As the medical device sector continues to rapidly evolve, it is becoming increasingly important to ensure that patients and healthcare professionals have access to up-to-date product and safety information. E-labelling provides a convenient way to share important information. Here, Schlafender Hase’s Peter Muller explores the advantages of e-labelling for the medical device sector, as well as providing some practical tips for getting ahead with the processes, procedures and solutions necessary for a successful transition to e-labelling.

E-labeling: The Road to Reduced Medical Device Packaging Material

E-labeling: The Road to Reduced Medical Device Packaging Material

New directives and guidance aim to connect patients, physicians and other stakeholders across the healthcare ecosystem with a consistently up-to-date information source for product and safety information that isn’t dependent on paper. Schlafender Hase’s Peter Muller explores the promise of e-labeling and practical next steps required to deliver on these directives.

Digital Transformation of Medical Device Labelling: A Practical Guide

Medical Device Labelling

By allowing medical device suppliers to provide up-to-date, reliable product and safety information in a secure and accessible format, e-labelling has the potential to revolutionise how medical professionals and patients access and manage information. In this article, Peter Muller of Schlafender Hase examines the potential of e-labelling and recommends practical steps to secure the benefits of e-labelling.

Change Management

life sciences industry

As they try to plug the gaps, and hang on to the qualified and experienced experts they already have, life sciences companies need to be clever about how they support those people to make best use of the time, and how they alleviate the aspects of their job which add the least value professionally yet cannot be skimped on.

Adapt to Survive

prominent trends in life sciences

No market is immune to change, and life sciences continues to face its fair share of upheaval as the industry accommodates emerging innovation in healthcare and a raft of other challenges to the status quo. Below are five of the most prominent trends and what they mean in practice.

Counting the Cost of Corrections in Clinical Trials Labeling

Correction Cycles

Within all of this, the clinical trials process carries its own particular share of risks and associated costs. If drugs do not pass human testing – and most don’t – all of the work that precedes this will have been for nothing: certainly it will not deliver the expected return. So life sciences companies need robust processes in place to ensure that products are taken absolutely correctly, leaving no scope for error in dosage, for example.

The Long Arm of the Regulator

prominent trends in life sciences

It is no coincidence that the food and nutraceuticals industries are now beginning to look to these more experienced sectors – particularly pharma – for guidance on best practices – and as a source of regulatory professionals as they seek to bolster their teams.

Food and Pharma: The Broadening Reach of Regulators

Food and Pharma Regulators

Its new Nutrition Facts label guidance, which applies to packaged foods, will ensure that labelling reflects the latest scientific information, including the link between diet and chronic diseases, for example. New requirements also include updated serving sizes, and a refreshed design which highlights information such as calorie content, portion size, added sugar content. New nutrients must be declared too, including Vitamin D and potassium, to combat associated deficiencies.

Food Follows Pharma into Tighter Regulatory Territory

Food Follows Pharma into Tighter Regulatory Territory

In the fast-growing nutraceuticals market, rules are becoming stricter too. Authorities in Scandinavia are clear that if nutrition companies are going to start making medicinal claims about their products, they must categorise themselves as pharmaceutical businesses and be bound by similar requirements. And countries from Japan and India to Canada have already put the regulatory wheels in motion.